eligibility_summary
Eligibility: Relapsed/refractory multiple myeloma after ≥3 prior lines, or relapsed/refractory non-Hodgkin lymphoma after ≥2 systemic regimens. Requires ECOG 0–1 and life expectancy >12 weeks. Excludes significant cardiac disease, HIV, hepatitis B (active) or hepatitis C infection, active COVID-19, and untreated CNS/epidural/brain metastases.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06119685 tests IDP-023, an off-the-shelf allogeneic natural killer (NK) cell therapy, alone or with IL-2 and antibodies in relapsed/refractory multiple myeloma (MM) and non-Hodgkin lymphoma (NHL). Mechanisms: IDP-023 mediates innate NK cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC) via FcγRIIIa/CD16. IL-2 (cytokine) boosts NK proliferation/activation via IL-2R/JAK-STAT. Rituximab (anti-CD20 mAb) targets B-cell NHL, daratumumab and isatuximab (anti-CD38 mAbs) target MM plasma cells—antibodies opsonize tumors to engage NK ADCC. Cyclophosphamide + fludarabine (lymphodepleting chemo) improve NK engraftment, Mesna is uroprotective. Targets: CD20+ B cells, CD38+ myeloma cells, and NK activation pathways (CD16, IL-2R).